

Customer No. 28880

Confirmation No.

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/743,852
Filing Date	December 22, 2003
First Named Inventor	Rocco Dean Gogliotti, et al.
Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	PC 25547A-EJB

Total Number of Pages in This Submission

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to a Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Statement as Provided by 37 CFR 1.97(b) Postcard
<b>Remarks</b> AUTHORIZATION TO CHARGE THE FEE AND ANY ADDITIONAL FEES AS NECESSARY OR CREDIT ANY OVERPAYMENT TO DEPOSIT ACCOUNT 23-0455 IS HEREBY GIVEN.		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual	Eric J. Baude	Reg No.: 47413
Signature	<i>Eric J. Baude</i>	
Date	March 4, 2004	

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date <u>3/4/04</u>			
Typed or printed	Cicely Bohms		
Signature	<i>Cicely Bohms</i>	Date	3/4/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

USPTO Fax No. 703-872-9306



PC 25547A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/743,852  
Applicant : Rocco Dean Gogliotti, et al.  
Filed : December 22, 2003  
Title : "BENZOXAZINES AND DERIVATIVES THEREOF AS  
THERAPEUTIC AGENTS"  
TC/AU :  
Examiner :  
Docket No. : PC25547A  
Customer No. :

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(b))**

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

The Information Disclosure Statement submitted herewith is being filed before the mailing of the first Office Action on the merits.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. §1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Authorization is hereby given to charge the required fee under 37 C.F.R. §1.17(p), any other necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Respectfully Submitted,

Dated: March 4, 2004

  
ERIC BAUDE  
Registration No. 47,413  
Warner -Lambert Company  
2800 Plymouth Road  
Ann Arbor, Michigan 48105  
Telephone: (734) 622-2095  
Facsimile: (734) 622-1553

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

**Complete if Known**

Application Number	10/743,852
Filing Date	December 22, 2003
First Named Inventor	Rocco Dean Gogliotti
Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	PC 25547A

Sheet	1	of	4
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> *Number <sup>4</sup> *Kind Code <sup>5</sup> (if known)				
		WO 01/53266				
		WO 01/81346				
		EP 1277738				

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/730680
				Filing Date	December 8, 2003
				First Named Inventor	Nicole Barvian, et al.
				Art Unit	Not Yet Known
Examiner Name	Not Yet Known				
Sheet	2	of	4	Attorney Docket Number	PC 50508

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ANDREI, et al., Somatic Mutation and Homozygous Deletion of PTEN/MMAC1 Gene 10q23 in Renal Cell Carcinoma, Anticancer Research, 1999, pp 3841-3846, Vol 19	
		BORLANDO, et al., Increase phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo, FASEB J., May 2000, pp. 895-903, Vol 14	
		BRASS, et al., DNA Amplification on Chromosome 3q26.1-q26.3 in Squamous Cell Carcinoma of the Lung Detected by Reverse Chromosome Painting, Eur. J. Cancer, 1996, pp 1205-1208, Vol 32A(7), Great Britain	
		FORGACS, et al., Mutation analysis of the PTEN/MMAC1 gene in lung cancer, Oncogene, 1998, pp 1557-1565, Vol 17	
		HIRSCH, et al., Central Role for G Protein-Coupled Phosphoinositide 3-Kinase $\gamma$ in Inflammation, Science, February 2000, pp 1049-1053, Vol 287, USA	
		HIRSCH, et al., Resistance to thromboembolism in PI3K-deficient mice, FASEB Journal, July 2001, pp. 2019-2021, USA	
		HU, et al., Inhibition of Phosphatidylinositol, 3'-Kinase Increases Efficacy of Paclitaxel in Vitro and in Vivo Ovarian Cancer Models, Cancer Res., February 2002, pp. 1087-1092, Vol 62	
		JIMENEZ, et al., Identification and characterization of new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase, EMBO Journal, 1998, pp 743-753, Vol 17(3), USA	
		KATSO, et al., Cellular Function of phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and Cancer, Annu. Rev. Cell Dev. Biol. 2001, pp 615-675, Vol 17, USA	
		KOTELEVETS, et al., Inhibition by Platelet-activating Factor of Src- and Hepatocyte Growth Factor-dependent Invasiveness of Intestinal and Kidney Epithelial Cells, J. Biol. Chem., June 1998, pp 14138-14145, Vol 273(23), USA	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/743,852
				Filing Date	December 22, 2003
				First Named Inventor	Rocco Dean Gogliotti, et al
				Art Unit	Not Yet Known
				Examiner Name	Not Yet Known
Sheet	3	of	4	Attorney Docket Number	PC 25547A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		KRCHAK, et al., A solid phase traceless synthesis of quinoxalinones, Tetrahedron Letters, 2000, pp 2835-2838, USA	
		LEE, et al., Solid-phase combinatorial synthesis of 5-arylalkylidene rhodanine, Tetrahedron Letters, 2000, pp 5729-5732, USA	
		LEE, et al., The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia, Leukemia, 2002, pp 486-507, Vol 16, USA	
		LEOPOLDT, et al., GBY Stimulates Phosphoinositide 3-Kinase-γ by Direct Interaction with Two Domains of the Catalytic p110 Subunit, December 1997, pp 7024-7029, Vol 273(12), USA	
		MA, et al., PIK3CA as an oncogene in cervical cancer, Oncogene, 2000 pp 2739-2744, Vol 19,	
		NAKANISHI, et al., Novel Functions of Phosphatidylinositol 3-Kinase in Terminally Differentiated Cells, Cellular Signalling, 1995, pp 545-557, Vol 6, Great Britain	
		PHILP, et al., The Phosphatidylinositol 3'-kinase p85α Gene Is an Oncogene in Human Ovarian and Colon Tumors <sup>1</sup> , Cancer Research, October 2001, pp 7426-7429, Vol 61, USA	
		SHAYESTEH, et al., PIK3CA is implicated as an oncogene in ovarian cancer, Nature Genetics, January 1999, pp. 99-102, Vol 21	
		SUSA, et al., Platelet-derived Growth Factor Activates Membrane-associated Phosphatidylinositol 3-Kinase and Mediates Its Translocation from the Cytosol, November 1992. Pp 22951-22956, Vol 267(32), USA	
		VANHAESEBROECK, et al., p110δ, a novel phosphoinositide 3-kinase in leukocytes, Proc. Natl. Acad. Sci., April 1997, pp. 4330-4335, Vol. 94, USA	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/743,852
				Filing Date	December 22, 2003
				First Named Inventor	Rocco Dean Gogliotti, et al
				Art Unit	Not Yet Known
				Examiner Name	Not Yet Known
Sheet	4	of	4	Attorney Docket Number	PC 25547A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		VIVANCO, et al., The Phosphatidylinositol 3-Kinase-Akt Pathway in Human Cancer, Nature Reviews Cancer, July 2002, pp. 489-501, Vol 2, USA	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.